Dyne Therapeutics (DYN) Interest Expenses (2025)

Dyne Therapeutics (DYN) has reported Interest Expenses for 8 consecutive years, with $88.7 million the latest figure, recorded in Q2 2026.

• In Q2 2026, Interest Expenses changed N/A year-over-year to $88.7 million; the TTM figure through Jun 2026 stood at $88.7 million (up 1611.42% YoY), while the FY2025 annual figure was $419.2 million, up 45.23% from the prior year.
• Interest Expenses improved to $88.7 million in Q2 2026 per DYN's latest filing, from $49.4 million in the prior quarter.
• Across five years, Interest Expenses topped out at $178.0 million in Q2 2024 and bottomed at $2.5 million in Q4 2025.
• Historically, Interest Expenses has averaged $55.1 million across 5 years, with a median of $29.3 million in 2023.
• Annual changes were most pronounced in 2022 — Interest Expenses soared 55871.43% — and 2024, when it tumbled 96.58%.
• Dyne Therapeutics' Interest Expenses stood at $113.6 million in 2022, then increased by 28.3% to $145.8 million in 2023, then sank by 96.58% to $5.0 million in 2024, then sank by 48.89% to $2.5 million in 2025, then jumped by 3384.68% to $88.7 million in 2026.
• Business Quant data shows DYN's Interest Expenses at $88.7 million in Q2 2026, $49.4 million in Q1 2026, and $2.5 million in Q4 2025.